Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dermatological Medicine
Volume 2016, Article ID 7296572, 3 pages
Case Report

Acquired Localized Hypertrichosis Induced by Rivastigmine

1Department of Dermatology, Hospital Universitario Severo Ochoa, Avenida de Orellana, Leganés, 28911 Madrid, Spain
2Department of Dermatology, Hospital Clinic, Carrer de Villarroel 170, 08036 Barcelona, Spain
3Department of Pathology, Hospital Universitario Severo Ochoa, Avenida de Orellana, Leganés, 28911 Madrid, Spain

Received 19 January 2016; Revised 24 February 2016; Accepted 7 March 2016

Academic Editor: Jeung-Hoon Lee

Copyright © 2016 Adrian Imbernón-Moya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hypertrichosis is the excessive hair growth in any area of the skin surface. Acquired localized hypertrichosis may be secondary to multiple causes and there is a secondary form due to several drugs, which is usually reversible with discontinuation of the causative agent. Rivastigmine is a reversible and competitive inhibitor of acetylcholinesterase and butyrylcholinesterase used for symptomatic treatment of Alzheimer dementia and Parkinson’s disease. It has an adequate safety profile and cutaneous side effects are unusual. Irritant contact dermatitis, allergic dermatitis, baboon syndrome, and cutaneous rash due to rivastigmine have been reported. We report on a Caucasian 80-year-old male with personal history of Alzheimer’s disease. The patient started therapy with oral rivastigmine one month prior to clinical presentation of localized hypertrichosis on both forearms. Norgalanthamine has been shown to promote hair growth activity via the proliferation of dermal papilla. Acetylcholinesterase inhibitors can induce hair growth.